论文部分内容阅读
目的研究CT增强扫描中欧乃派克的不良反应及应对方法。方法选择2013年6月-2015年5月于本院行CT增强扫描并应用欧乃派克为对比剂的患者1256例,将所有患者按照随机分组的方式分为对照组和研究组,对照组患者接受CT增强扫描,观察成功患者注射欧乃派克前以及注射后0h-48h内血清学、肾功能、心电图以及其他不良反应情况,研究组患者除了接受上述干预外,还需要接受循证护理干预。结果对照组患者在注射欧乃派克前,其血清学、肾功能、心电图结果以及其他不良反应情况与研究组患者无显著差异,但是在注射欧乃派克后其肾功能及心电图异常发生率以及不良反应发生率显著高于研究组(P<0.05),两组患者血清学检测不存在显著差异。结论 CT增强扫描中欧乃派克尽管不良反应发生率相对较低,但仍需引起重视,必须选择恰当的应对方法。
Objective To study the adverse reactions of Europa Park in CT enhanced scanning and its coping methods. Methods From June 2013 to May 2015, 1256 patients underwent CT enhanced scanning with Omnipaque contrast agent in our hospital. All patients were randomly divided into control group and study group. Patients in control group CT scan was performed to observe the serological, renal function, electrocardiogram (ECG) and other adverse reactions before and after the injection of Orpacud in successful patients. In addition to the above interventions, study group patients also received evidence-based nursing intervention. Results In the control group, there was no significant difference in the serological, renal function, electrocardiogram results and other adverse reactions between the study group and the patients before the injection of Omni Parker. However, the incidence of renal dysfunction and electrocardiogram abnormality after the injection of Omni Parker The incidence of the reaction was significantly higher than that of the study group (P <0.05), and there was no significant difference between the two groups in the serological test. Conclusion Although the incidence of adverse reactions in CT scan is still relatively low, Europapac still needs attention. Therefore, it is necessary to choose the appropriate coping method.